David S. Goldfarb, PA

David Goldfarb practices at Capital Nephrology Surgery Center in Sacramento, California.

David Goldfarb's NPI, 1144333642, was assigned on August 17, 2006. David Goldfarb holds California license PA21376.

David Goldfarb's primary practice is Capital Nephrology Surgery Center, at 1111 Exposition Blvd, Sacramento, CA 95815. The practice phone is (916) 564-6232.

David Goldfarb's primary practice is Capital Nephrology Surgery Center in Sacramento, California. The medical group on file is Sacramento Ear, Nose & Throat. Dmand AI also links David Goldfarb to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where David Goldfarb practices, 2 sites in all. Vendor and product names are available with a free account.

Physician assistant is David Goldfarb's primary specialty in the NPI Registry, under taxonomy code 363A00000X. David Goldfarb is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Dmand AI has David Goldfarb's licenses on file in 2 states: California and Florida.

Dmand AI lists acute sinusitis, chronic sinusitis, ear eustachian tube disorders, ear infection, itchy rashes, larynx and vocal cord disease, scalp rash and swimmer's ear among the conditions David Goldfarb treats.

CMS data shows 1,551 Medicare services from David Goldfarb across 12 procedure codes in 2024, for 467 Medicare patients. Medicare paid $56,262 for them. Every service was in an office.

CMS counts 467 Medicare patients who saw David Goldfarb in 2024. The largest group is 65 to 74, with 181 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 55% are also on Medicaid. Their average risk score is 1.32, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts David Goldfarb's median patient age at 71, with 53% women.

In 2024, David Goldfarb wrote 319 Medicare Part D claims for 161 patients. 98% of them were for generic drugs. CMS names the drug for 229 of them, across 7 drugs with 11 or more claims each, at $3,782 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 74 out of 100 for David Goldfarb for performance year 2024, reported as part of a group. David Goldfarb accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 1 general payment to David Goldfarb from 1 drug or device company in 2025. Food and beverage make up the largest share, 100% of the total. Novartis Pharmaceuticals Corporation paid the most, $35.